Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection

Allison Koenecke; Michael Powell; Ruoxuan Xiong; Zhu Shen; Nicole Fischer; Sakibul Huq; Adham M Khalafallah; Marco Trevisan; Pär Sparen; Juan J Carrero; Akihiko Nishimura; Brian Caffo; Elizabeth A Stuart; Renyuan Bai; Verena Staedtke; David L Thomas; Nickolas Papadopoulos; Ken W Kinzler; Bert Vogelstein; Shibin Zhou; Chetan Bettegowda; Maximilian F Konig; Brett D Mensh; Joshua T Vogelstein; Susan Athey

doi:10.7554/eLife.61700

. 2021 Jun 11;10:e61700. doi: 10.7554/eLife.61700

Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection

Allison Koenecke ^1,^†, Michael Powell ^2,^†, Ruoxuan Xiong ³, Zhu Shen ⁴, Nicole Fischer ⁵, Sakibul Huq ⁶, Adham M Khalafallah ⁶, Marco Trevisan ⁷, Pär Sparen ⁷, Juan J Carrero ⁷, Akihiko Nishimura ⁸, Brian Caffo ⁸, Elizabeth A Stuart ⁸, Renyuan Bai ⁶, Verena Staedtke ⁶, David L Thomas ⁵, Nickolas Papadopoulos ⁹, Ken W Kinzler ⁹, Bert Vogelstein ⁹, Shibin Zhou ⁹, Chetan Bettegowda ^5,⁹, Maximilian F Konig ^10,^✉, Brett D Mensh ^11,^✉, Joshua T Vogelstein ^2,^8,^†,^✉, Susan Athey ^12,^✉

Editors: Evangelos J Giamarellos-Bourboulis¹³, Jos WM van der Meer¹⁴

PMCID: PMC8195605 PMID: 34114951

Abstract

In severe viral pneumonia, including Coronavirus disease 2019 (COVID-19), the viral replication phase is often followed by hyperinflammation, which can lead to acute respiratory distress syndrome, multi-organ failure, and death. We previously demonstrated that alpha-1 adrenergic receptor (⍺₁-AR) antagonists can prevent hyperinflammation and death in mice. Here, we conducted retrospective analyses in two cohorts of patients with acute respiratory distress (ARD, n = 18,547) and three cohorts with pneumonia (n = 400,907). Federated across two ARD cohorts, we find that patients exposed to ⍺₁-AR antagonists, as compared to unexposed patients, had a 34% relative risk reduction for mechanical ventilation and death (OR = 0.70, p = 0.021). We replicated these methods on three pneumonia cohorts, all with similar effects on both outcomes. All results were robust to sensitivity analyses. These results highlight the urgent need for prospective trials testing whether prophylactic use of ⍺₁-AR antagonists ameliorates lower respiratory tract infection-associated hyperinflammation and death, as observed in COVID-19.

Research organism: None

Introduction

Each year, approximately 300 million people develop pneumonia (GBD 2016 Lower Respiratory Infections Collaborators, 2018), which usually results in appropriate, self-limiting immune responses and clearance of the bacterial or viral pathogen. In some cases (Figure 1), the pathogen overwhelms host defenses, causing massive lung damage and compromising other organs. In other patients, however, pathological immune activation (‘hyperinflammation') occurs in the lungs and systemically (Hay et al., 2017), resulting in immune-mediated end-organ damage that can compromise gas exchange. Dysregulated immune responses may lead to acute respiratory distress syndrome (ARDS), need for mechanical ventilation, and failure of other organ systems, contributing to the global pneumonia death toll of 3 million per year (The top 10 causes of death, 2021). The clinical picture is similar in Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2; hyperinflammation compromises organ function in the lungs and systemically, causing high morbidity and mortality (Zhou et al., 2020; Ruan et al., 2020; Qin et al., 2020; Huang et al., 2020).

Figure 1. — The timing and relation of hyperinflammation to specific organ manifestations of severe acute respiratory distress syndrome (ARDS) are areas of uncertainty and investigation.

Disease-modifying strategies for COVID-19 include targeting the virus and treating (or ideally preventing) secondary hyperinflammation with immunomodulatory or immunosuppressive drugs. Here, we propose an approach using the latter strategy of hyperinflammation prevention (Flierl et al., 2007; Shaked et al., 2015). Immune cells communicate with each other by secreting peptides called cytokines and chemokines, which initially amplify the response and later restore homeostasis after the threat has receded. However, in hyperinflammation, production of cytokines is dysregulated, forming a ‘cytokine storm’ that can damage healthy tissue and overwhelm the host.

COVID-19-associated hyperinflammation is characterized by profound elevation of many pro-inflammatory cytokines (Ruan et al., 2020; Huang et al., 2020; Mehta et al., 2020; McGonagle et al., 2020; Pedersen and Ho, 2020; Chen et al., 2020). Several immunosuppressive treatment approaches are being studied or used in clinical practice to ameliorate hyperinflammation-associated morbidity in patients who have already developed severe complications of COVID-19, including blocking specific cytokine signaling axes (e.g., IL-6, IL-1, or TNF-alpha) and broader immunosuppressive approaches (e.g. dexamethasone or baricitinib) (Investigators et al., 2021; RECOVERY Collaborative Group, 2021; Huet et al., 2020; Rosas et al., 2021; Salama et al., 2021; Stone et al., 2020). Dexamethasone is one of few drugs that have shown a mortality benefit in hospitalized patients with COVID-19 who require oxygen or mechanical ventilation, but glucocorticoids may not be beneficial - and may even be harmful - when given earlier in the disease course (RECOVERY Collaborative Group, 2021; Gianfrancesco et al., 2020). Conflicting data on tocilizumab and other inhibitors of IL-6 signaling in patients with severe COVID-19 suggests that immunosuppressive strategies may be of limited benefit once end-organ damage has developed (Investigators et al., 2021; Rosas et al., 2021; Salama et al., 2021; Stone et al., 2020; Lescure et al., 2021; Della-Torre et al., 2020), and highlight the importance of identifying drugs that can prevent dysregulated immune responses and immune-mediated damage.

Inhibition of catecholamine signaling has emerged as a promising approach to prevent hyperinflammation and related mortality. The catecholamine pathway, beyond its role in neurotransmission and endocrine signaling, is involved in immunomodulation of innate and adaptive immune cells. In mice, catecholamine release coincides with hyperinflammation and enhances inflammatory injury by augmenting cytokine production via a self-amplifying process that requires alpha-1 adrenergic receptor (⍺₁-AR) signaling (Staedtke et al., 2018). Catecholamine synthesis inhibition reduces cytokine responses and dramatically increases survival after inflammatory stimuli. The ⍺₁-AR antagonist prazosin (at clinically prescribed dosages)—but not beta-adrenergic receptor (β-AR) antagonists—offers similar protection, providing in vivo evidence that this drug class can prevent cytokine storm (Staedtke et al., 2018). These preclinical findings provide a rationale for clinical studies that assess whether ⍺₁-AR antagonists can prevent hyperinflammation and its sequelae associated with severe infection.

To date, no controlled trials have studied whether ⍺₁-AR antagonism improves clinical outcomes in patients with lower respiratory tract infection (pneumonia, acute respiratory distress syndrome, or COVID-19). Replicated retrospective cohort studies offer the highest level of evidence prior to prospective studies (Burns et al., 2011). We thus conducted a series of five retrospective cohort studies, spanning different populations, age groups, demographics, and countries.

Our primary research question is whether ⍺₁-AR antagonists (e.g., through its known modulation of hyperinflammation) can mitigate disease and prevent mortality. We operationalized this research question by testing the statistical hypothesis that patients exposed to ⍺₁-AR antagonists, as compared to unexposed patients, have a reduced risk of adverse outcomes in lower respiratory tract infection. We considered two outcomes (mechanical ventilation, and mechanical ventilation followed by death) and three exposures (any ⍺₁-AR antagonist, tamsulosin specifically, and doxazosin specifically). Tamsulosin is the most commonly used ⍺₁-AR antagonist in the United States and demonstrates a ‘uroselective’ binding pattern (predominantly inhibits ⍺_1A- and ⍺_1D-AR subtypes). In contrast, doxazosin is a non-selective ⍺₁-AR antagonist that demonstrates clinically significant inhibition of all three known ⍺₁-AR subtypes, including antagonism on the ⍺_1B-AR. This antagonism of ⍺_1B-AR expressed in the peripheral vasculature is thought to mediate the antihypertensive effects of doxazosin and related drugs. Importantly, all three ⍺₁-AR subtypes have been implicated in catecholamine signaling on immune cells, and signaling redundancy suggests a theoretical benefit for pan-⍺₁-AR antagonists (e.g., doxazosin or prazosin) in preventing catecholamine signaling and hyperinflammation. Relatively few patients in our samples are prescribed doxazosin, so we are only able to study this drug in our much larger pneumonia cohorts (since there is insufficient statistical power to analyze the drug in ARD cohorts).

Results

The statistical analysis plan described in Materials and methods was fixed across all cohorts (to the extent possible) to limit researcher degrees of freedom and to emulate a prospective trial (Dickerman et al., 2019). We computed the probabilities of outcomes, relative risk reductions (RRR), odds ratios (OR), confidence intervals (CI), and p-values (p) using an unadjusted model as well as adjusted and matched modeling approaches that account for demographic and health-related confounders. We focus our discussion of reported results on the adjusted model comparing patients exposed to ⍺₁-AR antagonists to unexposed patients. The adjusted model is an inverse propensity-weighted regression on a reduced sample satisfying propensity overlap; see Materials and methods for details.

Participants

We studied two cohorts of patients who were diagnostically coded with acute respiratory distress (ARD, a surrogate precursor state to ARDS) from two de-identified databases: the IBM MarketScan Research Database (which we refer to as MarketScan) and Optum’s Clinformatics Data Mart Database (OptumInsight, Eden Prairie, MN), a commercial and Medicare Advantage claims database (which we refer to as Optum). We further studied three cohorts of patients with pneumonia from the MarketScan, Optum, and Swedish National Patient Register (Patientregistret, 2021) databases. ICD codes were used to identify the first instance of inpatient admission for each patient in each cohort (see Materials and methods for details). Our main analysis employed federated analyses on the ARD cohort using pooled MarketScan and Optum results.

We limit the study to older men because of the widespread use in the United States of ⍺₁-AR antagonists as a treatment for benign prostatic hyperplasia (BPH), a diagnosis clinically unrelated to the respiratory system or immune disorders. Focusing on men over the age of 45 facilitated examining a patient population in which a large portion of the exposed group faced similar risks of poor outcomes from respiratory conditions as the unexposed group, thus mitigating confounding by indication.

We allowed a maximum age of 85 years to reflect the ongoing clinical trials investigating these interventions (Prazosin to Prevent COVID-19 (PREVENT-COVID Trial); https://clinicaltrials.gov/ct2/show/NCT04365257) . Figure 2 shows the CONSORT flow diagram for selecting patients from the four claims datasets (with slight modifications in the Swedish National Patient Register analysis to reflect different practices in that population); see Materials and methods for details. Focusing this study exclusively on older men limits the study’s internal validity to older men, and it would take additional assumptions to justify external validity claims including excluded demographic groups (e.g., women and younger patients). We nevertheless note that there is an important literature on demographic fairness with regard to clinical studies (Holdcroft, 2007; McMurray, 1991).

Figure 2. — Note that patients are considered exposed to ⍺₁-AR antagonists if they have a medication possession ratio ≥50 % in the prior year, and are considered unexposed if they have not taken any amount of ⍺₁-AR antagonists in the prior year. ARD inpatient visits are not considered between 2017–2018 as ARD ICD-9 codes were being phased out while ICD-10 codes for ARD were not yet commonly used. Within a single dataset (MarketScan or Optum), there exists some patient overlap for the two cohort diagnoses (pneumonia and ARD): 5,100 patients in MarketScan and 2,778 in Optum. This diagram only presents four of the five cohorts studied; the fifth cohort (the Swedish National Patient Register) uses a different set of inclusion/exclusion criteria (see section Sweden National Patient Register for criteria description, and Figure 3—figure supplement 1 for information on dataset characteristics).

Cohort-specific results

We conducted the same statistical analysis in each of the five cohorts. In each cohort, we measured incidence and odds ratios (OR) for patients exposed to any ⍺₁-AR antagonist, or tamsulosin specifically, as compared to unexposed patients, for each outcome. In the two largest pneumonia cohorts, we additionally consider doxazosin exposure. Our main analysis, described in the following section, involves pooling the results from individual cohorts. For the sake of completion, Figure 3—figure supplements 1–5 show results for each of the five individual cohorts. We generally found a positive RRR given any combination of exposure and outcome, and found that the adjusted model yielded ORs consistently less than 1. In all cohorts, the OR point estimates were robust to model changes, including other doubly robust approaches (Funk et al., 2011) such as causal forests (Wager and Athey, 2018), each of which yielded similar results to those presented here.

Federated results

We employed federated causal methods to enable combining patient-level results while maintaining patient privacy and data usage agreement constraints; see Materials and methods for details. We pooled results across MarketScan and Optum for each of the ARD and pneumonia cohorts (the Swedish dataset used a different outcome because ventilation was not reliably coded, so we did not pool these results). For ARD patients (n = 18,547) exposed to any ⍺₁-AR antagonist, as compared to unexposed ARD patients, we found for ventilation and death: RRR = 34%, OR = 0.70, 95% CI (0.49–0.99), p = 0.021; for pneumonia patients (n = 338,674) we found: RRR = 8%, OR = 0.86, 95% CI (0.82–0.91), p < 0.001 (Figure 3). The treatment effect was similar across the outcome of ventilation only, exposure to tamsulosin only, and other analysis methods (unadjusted and matched), with ORs consistently less than 1. Doxazosin, a non-selective ⍺₁-AR antagonist hypothesized to have a greater efficacy than other ⍺₁-AR antagonists, demonstrated a twofold stronger effect than tamsulosin, which blocks fewer ⍺₁-adrenoreceptors.

Figure 3. — In each quadrant, we show: (left) plotted odds ratios (OR) with confidence intervals (CI), and (right) values for relative risk reductions (RRR), OR, CI, p-values (p), and sample sizes (n) for unadjusted, adjusted, and matched models, including any ⍺₁-AR antagonists or specifically tamsulosin or doxazosin. We only study exposure to doxazosin in the pneumonia cohorts since there is insufficient statistical power to analyze the drug in ARD cohorts. Results are shown for outcomes of mechanical ventilation (left column) and mechanical ventilation leading to death (right column). In general, ⍺₁-AR antagonists were associated with reducing risk of adverse events across exposures, outcomes, and modeling approaches. Each federated analysis yielded an OR point estimate below 1.

Figure 3—figure supplement 1. — In each quadrant, we show: (left) plotted odds ratios (OR) with confidence intervals (CI), and (right) values for relative risk reductions (RRR), OR, CI, p-values (p), and sample sizes (n) for unadjusted, adjusted, and matched models, including any ⍺₁-AR antagonists or specifically tamsulosin or doxazosin. We only study exposure to doxazosin in the pneumonia cohorts since there is insufficient statistical power to analyze the drug in ARD cohorts. Results are shown for outcomes of mechanical ventilation (left column) and mechanical ventilation leading to death (right column). In general, ⍺₁-AR antagonists were associated with reducing risk of adverse events across exposures, outcomes, and modeling approaches. Each federated analysis yielded an OR point estimate below 1.

Discussion

The results of this retrospective clinical study extend preclinical findings to support the hypothesis that ⍺₁-AR antagonists may reduce morbidity and mortality in patients at risk of hyperinflammation (Konig et al., 2020). A challenge resolved by our retrospective analysis is that patients exposed to ⍺₁-AR antagonists may differ from unexposed patients in ways that might also affect their outcomes from respiratory diseases. Individuals are often prescribed ⍺₁-AR antagonists for chronic diseases, and we consider only patients who used the medications for at least 6 months in the year prior (i.e., for a medical possession ratio of at least 50%) to the index hospital admission for pneumonia or ARDS where we measure patient outcomes. This makes it less likely that the unmeasured severity of respiratory illness at time of admission for our patient population differs substantially between exposed and unexposed groups; however, we cannot rule out such differences. We refer to confounders as factors that vary between patients exposed and unexposed to ⍺₁-AR antagonists and also relate to patient outcomes. One important confounder is age, which in turn is related to other health conditions. For this reason, our research design (outlined in more detail in the Materials and methods section) includes several approaches to adjusting for observed demographic and health-related confounders.

Given that older men were generally using ⍺₁-AR antagonists for reasons unrelated to ARDS, it was feasible to balance the exposed and unexposed groups on a large set of prognostically important covariates, reducing concerns that differences in outcomes might be due to confounding. Nonetheless, there is an urgent need for randomized prospective trials to further test this hypothesis in patients with COVID-19 and other lower respiratory tract infections. In such trials, early administration of ⍺₁-AR antagonists prior to development of severe symptoms is preferred because the goal is to prevent, rather than treat, hyperinflammation-related damage. While this study could only examine medications received outside the inpatient environment due to dataset limitations, future work should attempt to address whether continued use of ⍺₁-AR antagonists by hospitalized patients is important for preventing severe symptoms. Additionally, future work should consider whether the patients’ respiratory illness is community- or hospital-acquired (Whittle et al., 1997).

⍺₁-AR antagonists with various receptor subtype characteristics have been used to treat millions of patients with BPH, hypertension, and other disorders. This history supports their safety profile (Yasukawa et al., 2001), although caution is warranted in using any medication for the first time in a new disease such as COVID-19. Given the poorly understood relationship between COVID-19 severity and hypertension (Konig et al., 2020), it is important to note that nonselective (⍺_1A=⍺_1B=⍺_1D) ⍺₁-ARs (e.g., prazosin and doxazosin) are often primarily used to reduce blood pressure, whereas subtype-selective (⍺_1A=⍺_1D>⍺_1B) ⍺₁-ARs (e.g. tamsulosin) have fewer hemodynamic effects. However, given the known redundancy of catecholamine signaling (Grisanti et al., 2011), we expect ⍺₁-AR antagonists that inhibit all three ⍺₁-AR subtypes (e.g. prazosin and doxazosin) to be more efficacious in the prevention of hyperinflammation.

⍺₁-AR antagonists are inexpensive and administered orally, enabling widespread use if prospective trials support their efficacy and safety. Beyond COVID-19 and other lower respiratory tract infections, ⍺₁-AR antagonists may also reduce hyperinflammation and their sequelae in adoptive cell therapy (‘cytokine release syndrome’) and autoimmune rheumatic disease.

Materials and methods

Study definitions

Patients were considered exposed if they were users of ⍺₁-AR antagonists (doxazosin, alfuzosin, prazosin, silodosin, terazosin, or tamsulosin). ⍺₁-AR antagonist usage is defined by having a medication possession ratio ≥50 % (i.e., a minimum prescribed supply covering six of the last 12 months) for a qualifying drug in the year prior to the first inpatient admission date for ARD or pneumonia. In additional analyses, we used the same definition to consider exposed patients who were taking tamsulosin or doxazosin. Patients are considered unexposed if they have never been prescribed the relevant drug class or drug within the year prior to the admission date. We exclude patients having a medical possession ratio greater than 0% and less than 50% of the relevant drug class or drug (equivalently, we exclude patients who do use ⍺1-AR antagonists, but for less than 6 months of the prior year). While all patients from the MarketScan, Optum, and Swedish National Patient Register (Patientregistret, 2021) databases were restricted to a 45–85 year age range, the MarketScan database only includes patients up to age 65 due to Medicare exclusion; we adjust for age in our analyses. The data used in this study do not include ⍺₁-AR antagonist usage during the ARD or pneumonia admission.

The first instances of ARD or pneumonia inpatient admissions for each patient were identified using ICD codes. Because the MarketScan database only includes United States patient data through fiscal year 2016, we only used ICD-9 codes to identify diagnoses from this database. The Optum database includes United States patient data from fiscal year 2004 through 2019, allowing for use of both ICD-9 and ICD-10 codes to identify diagnoses. The Swedish data contained only ICD-10 codes. To identify ARD, we used the ICD-9 code 518.82 and the ensuing ICD-10 code of R.0603, noting that the latter code was only available from 2018 onwards; hence, the Optum ARD cohort included only patients identified by their first inpatient admission for an ARD diagnosis occurring either from 2004 to 2015 or from 2018 to 2019. To identify pneumonia, we used the Agency for Healthcare Research and Quality (AHRQ) pneumonia category for both ICD-9 and ICD-10 codes.

We considered the following potential confounders: age, fiscal year, total weeks with inpatient admissions in the prior year, total outpatient visits in the prior year, total days as an inpatient in the prior year, total weeks with inpatient admissions in the prior two months, and comorbidities identified from healthcare encounters in the prior year: hypertension, ischemic heart disease, acute myocardial infarction, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, and cancer. All comorbidities were defined according to ICD code sets provided by the Chronic Conditions Data Warehouse (Condition Categories, 2020). The numeric confounders relevant to prior inpatient and outpatient visits were log-transformed; all confounders were de-meaned and scaled to unit variance.

The outcomes of interest in this study included mechanical ventilation and death. Mechanical ventilation was tabulated as an outcome for patients receiving a procedure corresponding to one of the following ICD-9 codes (967, 9670, 9671, 9672) or ICD-10 codes (5A1935Z, 5A1945Z, 5A1955Z). When tabulating death outcomes, we note a difference in death encoding among databases. From the MarketScan database, we identified death outcomes by in-hospital deaths noted in claims records. From the Optum database, in-hospital death data were unavailable, so we instead identified death outcomes by whether a patient’s month of death (if observed) was within 1 month of the relevant ARD or pneumonia inpatient visit month. For both databases, our analyses studied the outcome of death (as defined above) occurring along with mechanical ventilation during inpatient stay. The Swedish National Patient Register’s in-hospital deaths were tabulated in a similar manner to the MarketScan database. We focused on death associated with respiratory failure to avoid counting deaths due to other diseases (many of the patients were hospitalized for other reasons), but note that our findings are robust to outcomes defined instead by all-cause mortality, with OR <1. This analysis mirrored our prospective trial design (Prazosin to Prevent COVID-19 (PREVENT-COVID Trial); https://clinicaltrials.gov/ct2/show/NCT04365257).

Unadjusted analysis

In our baseline unadjusted analysis, we used Fisher’s exact test to compare the probability of outcome occurrence with ⍺₁-AR antagonist exposure versus without. Fisher’s exact test and the associated non-central hypergeometric distribution under the alternative provided the odds ratios, confidence intervals, and p-values (one-sided) reported for individual cohorts. We additionally computed the relative risk reduction (RRR).

Adjusted analysis

We nonparametrically estimated (using generalized random forests Athey et al., 2019) propensity scores and restricted analyses to those individuals with probabilities of being exposed (and of receiving the unexposed condition) between the maximum of the 1st percentiles and the minimum of the 99th percentiles of propensity scores across exposed and unexposed groups (Stürmer et al., 2010). This (propensity score trimming) step prevents the comparison of individuals with an extremely low estimated chance of receiving one of the three exposures. We refer to this as our reduced sample. We note that our results are robust to different definitions of propensity score trimming, such as restricting to propensity scores between 0.01 and 0.99.

On the reduced sample, we then apply estimation techniques designed for causal inference to compare the probability of outcome occurrence with ⍺₁-AR antagonist exposure versus without. Specifically, we invoke inverse propensity-weighting, which reweights the unexposed population such that on average, the reweighted population more closely resembles the exposed population in terms of observed characteristics. Doing so yields better balancing of covariates, as seen in the pre- and post-inverse-propensity-weighting comparison in Figure 3—figure supplement 2 (ii)–5(ii). To obtain an odds ratio, we fit an inverse propensity-weighted logistic regression model. This approach is ‘doubly robust’ in that it yields valid estimates of causal effects if we have (1) observed all relevant confounders and (2) either one of the logistic regression model or the propensity score model is correctly specified. To estimate confidence intervals we used a Wald-type estimator. To obtain one-sided p-values we invoked classical asymptotic theory.

Matched analysis

An alternative approach comparing patients exposed to ⍺₁-AR antagonists with unexposed patients who are as similar as possible—and thus mimicking a randomized controlled trial—involves statistical matching, where each exposed patient is compared to a set of ‘nearest neighbors’ measured in terms of characteristics. This approach avoids making specific functional form assumptions about the relationship between characteristics and outcomes (Stuart, 2010). Specifically, on the reduced sample, we performed a 5:1 matching analysis (Stuart, 2010), assigning five unexposed patients to each exposed patient (i.e., patients exposed to any ⍺₁-AR antagonist or specifically tamsulosin or doxazosin) and then comparing the outcome of the exposed patient to the average outcome for matched unexposed patients. We required an exact match on patient age and then used a greedy, nearest neighbor approach based on Mahalanobis distance with a caliper of 0.2 on the remaining covariates (Ho et al., 2011). We then used the Cochran-Mantel-Haenszel (CMH) test on this matched sample to provide the odds ratios, 95% confidence intervals, and p-values associated with the hypothesis of no effect.

To elaborate, the CMH test can be thought of as a generalization of the chi-square test for association (Mantel and Haenszel, 1959). Fisher’s exact test considers single 2 × 2 contingency tables containing the counts for two dichotomous variables, specifically an outcome indicator and an exposure indicator (for the setting in this paper). In contrast, the CMH test applies to an array of k contingency tables such that the 2 × 2 × k array of tables represents a stratification of the data into k groups or matched pairs that can be considered comparable (typically groups are defined by the realization of some set of categorical variables) aside from their outcome and exposure values. For each single-source (e.g., MarketScan or Optum) matched model we compiled 2 × 2 contingency tables for exposure and outcome values for the matched pairs obtained exclusively from that database. We then conducted a CMH test on each array of 2 × 2 contingency tables separately. Let k_M represent the number of such tables in the MarketScan data set and k_O be the number of such tables in the Optum data set. In both cases k corresponds to the number of exposed observations for which suitable matches could be identified.

Federated analysis

Pooling the unadjusted models leveraged the CMH test by considering all observations from each data set to be ‘matched’ with other observations from the same data set according to one categorical variable: the source database. Thus, each database contributed a single 2 × 2 contingency table to form the 2 × 2 × 2 array evaluated by the CMH test.

To pool the MarketScan and Optum adjusted models, we calculated the pooled coefficient and variance of the exposure using inverse variance weighting (Hartung et al., 2011). Let $\hat{β_{i}}$ and $V a r (\hat{β_{i}})$ be the estimated coefficient and variance of the exposure on dataset i. The pooled coefficient of the exposure is

{\hat{β}}_{p o o l e d} = \frac{\sum_{i} {\hat{β}}_{i} / V a r ({\hat{β}}_{i})}{\sum_{i} 1 / V a r ({\hat{β}}_{i})},

and the pooled variance of the exposure coefficient is

V a r ({\hat{β}}_{p o o l e d}) = \frac{1}{\sum_{i} 1 / V a r (\hat{β_{i}})} .

To pool the MarketScan and Optum matched models, we concatenated the 2 × 2 contingency tables for the matched pairs from MarketScan with the 2 × 2 contingency tables for the matched pairs from Optum. In this manner, we effectively pooled the two exposed populations and their matched unexposed populations without ever combining the raw data in any way. Of note, combining raw data was prohibited by both data use agreements. Matches for exposed patients came exclusively from each exposed patient’s source data set. The CMH test effectively processed a 2 × 2 × (k_M+ k_O) array of contingency tables.

Finally, we pooled the relative risk reductions (RRR) estimated from the two data sets using inverse variance weighting of the respective RRRs contributed from separate MarketScan and Optum analyses. First let relative risk reduction (RRR) be defined as

\hat{R R R} = \frac{\hat{p_{y}} - \hat{p_{x}}}{\hat{p_{y}}} = 1 - \frac{\hat{p_{x}}}{\hat{p_{y}}},

where X corresponds to the exposed group and Y corresponds to the unexposed group. Next, the variance of the RRR estimate can be derived as the variance of a ratio of two binomial proportions:

V a r (\hat{R R R}) = V a r (\frac{\hat{p_{x}}}{\hat{p_{y}}}) = \frac{1}{n_{x}} \frac{\hat{p_{x}} (1 - \hat{p_{x}})}{{\hat{p_{y}}}^{2}} + \frac{1}{n_{y}} \frac{{\hat{p_{x}}}^{2} \cdot \hat{p_{y}} (1 - \hat{p_{y}})}{{\hat{p_{y}}}^{4}} .

Finally, multiple RRR estimates are pooled using inverse variance weighting:

{\hat{R R R}}_{p o o l e d} = \frac{\sum_{i} {\hat{R R R}}_{i} / V a r ({\hat{R R R}}_{i})}{\sum_{i} 1 / V a r ({\hat{R R R}}_{i})} .

Sensitivity analysis

To assess the robustness of our results to alternative approaches to estimating causal effects under the unconfoundedness assumption (Steegen et al., 2016), we explored methods including inverse propensity-weighted (IPW) averaging of outcomes as well as the (doubly robust) augmented inverse propensity-weighted (AIPW) estimator, where we used alternatives such as logistic regression and non-parametric causal forests (Wager and Athey, 2018). To assess invariance of our results to definitional choices, we adjusted the definition of exposure to ⍺₁-AR antagonists (e.g., requiring regular use of ⍺₁-AR antagonists within the prior 3 months rather than 12 months, or excluding ⍺₁-AR antagonist users who simultaneously take one of the 12 most common drugs appearing in the cohorts studied) as well as the definitions of certain confounders (e.g., combining three cardiovascular confounders into one indicator, including different metrics of prior inpatient or outpatient stays, including comorbidity severity indices, or including additional comorbidities such as HIV infection). The results using these alternate methods and definitions were consistent with those presented in the results section.

Further, we sought to observe the time course of health decline in the exposed and unexposed groups (quantified as the number of inpatient visits in the months prior to a patient’s target admission date). This analysis shows similar temporal trends for the exposed and unexposed groups, indicating that neither group was declining more rapidly than the other; see Figure 4.

Figure 4. — Both exposed and unexposed groups had similar trends of declining health leading up to the target admission date, where health decline is defined as having more frequent inpatient visits.

Figure 4—figure supplement 1. — Both exposed and unexposed groups had similar trends of declining health leading up to the target admission date, where health decline is defined as having more frequent inpatient visits.

Lastly, following Rosenbaum and Rubin, 1983, we assessed the sensitivity of our estimate of the treatment effect to the presence of an unobserved confounder. We estimated the E-value (VanderWeele and Ding, 2017), which represents ‘the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the treatment and the outcome to fully explain away a specific treatment-outcome association, conditional on the measured covariates’ (VanderWeele and Ding, 2017). The ORs (and corresponding confidence interval) are defined by the relative odds of occurrence of an outcome (we focus on ventilation and death) given exposure to ⍺₁-AR antagonists. We calculated the E-value on both the OR point estimate and confidence interval, each of which has its own interpretation. The minimum odds ratio necessary for an unmeasured confounder (equally associated with both alpha-blocker exposure and the outcome) to move the estimated treatment effect to the null (i.e., OR = 1) is 2.2 for the federated ARD cohort and 1.6 for the federated pneumonia cohort; our findings could not be fully explained by a weaker confounder. The minimum odds ratio necessary for an unmeasured confounder to yield a confidence interval including 1 is an E-value of 1.1 for the federated ARD cohort and 1.4 for the federated pneumonia cohort; we continue to reject the null of no treatment effect in the presence of weaker confounding.

Sweden National Patient Register

The Swedish National Patient Register differed from the MarketScan and Optum databases in several key ways that motivated slight modifications to the analysis. First, we had access to data from 2006 to 2012, during which time the US used ICD-9 and Sweden used ICD-10. Second, in Sweden, ventilation is not often coded, so we instead only considered the outcome of in-hospital death, which likely underestimates the effect size due to deaths from other causes. Nonetheless, the basic results are preserved in this complementary data set. Results are reported in Figure 3—figure supplement 1.

Acknowledgements

Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1 TR001085) and from Internal Stanford funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.We thank Adam Sacarny (Columbia University) for advice on processing and analyzing health care claims data. Dr. Sacarny was not compensated for his assistance. We thank Sandra Aamodt for reviewing and editing the manuscript, and Julia Kuhl and Eric Bridgeford for help generating the figures. We also acknowledge Marc Succhard and Sascha Dublin for helpful discussions. Research, including data analysis, was partially supported by funding from Microsoft Research and Fast Grants, part of the Emergent Ventures Program at The Mercatus Center at George Mason University. Allison Koenecke was supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE – 1656518. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. Dr. Konig was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award no. T32AR048522. Dr. Bettegowda was supported by the Burroughs Wellcome Career Award for Medical Scientists. Dr. Stuart was supported by the National Institute of Mental Health under Grant R01MH115487. Dr. Staedtke was supported by the National Cancer Institute NCI 5K08CA230179 and 1U01CA247576 and the Sontag Distinguished Scientist Award. Dr. Bai was supported by the National Cancer Institute NCI 1U01CA247576. JJC is supported by the Swedish Research Council (#2019–01059) and the Swedish Heart and Lung Foundation. This work was further supported by The Virginia and DK Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, and the BKI Cancer Genetics and Genomics Research Program.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Maximilian F Konig, Email: konig@jhmi.edu.

Brett D Mensh, Email: bmensh@gmail.com.

Joshua T Vogelstein, Email: jovo@jhu.edu.

Susan Athey, Email: athey@stanford.edu.

Evangelos J Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Medical School, Greece.

Jos WM van der Meer, Radboud University Medical Centre, Netherlands.

Funding Information

This paper was supported by the following grants:

Microsoft Research to Joshua T Vogelstein.
George Mason University Emergent Ventures Program to Joshua T Vogelstein.
National Science Foundation DGE – 1656518 to Allison Koenecke.
National Institute of Arthritis and Musculoskeletal and Skin Diseases T32AR048522 to Maximilian F Konig.
Burroughs Wellcome Fund to Chetan Bettegowda.
National Institute of Mental Health R01MH115487 to Elizabeth A Stuart.
National Cancer Institute 5K08CA230179 to Verena Staedtke.
National Cancer Institute 1U01CA247576 to Verena Staedtke.
National Cancer Institute 1U01CA247576 to Renyuan Bai.
Swedish Research Council #2019–01059 to Juan J Carrero.
Swedish Heart-Lung Foundation to Juan J Carrero.

Additional information

Competing interests

No competing interests declared.

Listed as an inventor on a patent application filed in 2017 by The Johns Hopkins University (JHU) (application number 20200368324) on the use of various drugs to prevent cytokine release syndromes. JHU will not assert patent rights from this filing for treatment related to COVID-19. NP is a founder of and holds equity in Thrive Earlier Detection. NP is on the Board of Directors of and a consultant to Thrive Earlier Detection. NP is a founder of, holds equity in, and serves as a consultant to Personal Genome Diagnostics. NP is a consultant to and holds equity in NeoPhore. NP is also an inventor on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies.

Listed as an inventor on a patent application filed in 2017 by The Johns Hopkins University (JHU) (application number 20200368324) on the use of various drugs to prevent cytokine release syndromes. JHU will not assert patent rights from this filing for treatment related to COVID-19. KWK is a founder of and holds equity in Thrive Earlier Detection. KWK is on the Board of Directors of and a consultant to Thrive Earlier Detection. KWK is a founder of, holds equity in, and serves as a consultant to Personal Genome Diagnostics. KWK is a consultant to Sysmex, Eisai, and CAGE Pharma and holds equity in CAGE Pharma. KWK is a consultant to and holds equity in NeoPhore. KWK is an inventor on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies.

Listed as an inventor on a patent application filed in 2017 by The Johns Hopkins University (JHU) (application number 20200368324) on the use of various drugs to prevent cytokine release syndromes. JHU will not assert patent rights from this filing for treatment related to COVID-19. BV is a founder of and holds equity in Thrive Earlier Detection. BV is a consultant to and holds equity in NeoPhore. BV is a founder of, holds equity in, and serves as a consultant to Personal Genome Diagnostics. BV is a consultant to Sysmex, Eisai, and CAGE Pharma and holds equity in CAGE Pharma. BV is also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies.

CB is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. CB is also an inventor on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies.

SA is an advisor and holds an equity stake in two private companies, Prealize (Palo Alto, California, USA) and Dr. Consulta (Brazil). Prealize is a health care analytics company, and Dr. Consulta operates a chain of low-cost medical clinics in Brazil.

Author contributions

Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing.

Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing.

Writing – original draft, Writing – review and editing.

Ethics

No human experiments were performed as this study was retrospective in nature and was conducted using third-party data. Research activity on population health on de-identified data has been judged exempt by the Stanford IRB, precluding consent and other requirements associated with human subjects research. Access to IBM MarketScanx Research Databases and Optum's Clinformatics Data Mart Database was granted through the Stanford Center for Population Health Sciences (PHS); access to the Swedish National Patient Register was approved by the regional ethical review board in Stockholm and the Swedish National Board of Welfare, and informed consent was waived. This research is covered under Stanford PHS protocol 40974.

Additional files

Source code 1. R Markdown code to run retrospective analysis and generate figures.

elife-61700-supp1.zip^{(28.5KB, zip)}

Source code 2. R script to generate cohorts and perform propensity matching.

elife-61700-supp2.zip^{(5.7KB, zip)}

Transparent reporting form

elife-61700-transrepform1.docx^{(246KB, docx)}

Data availability

Data for these analyses were made available to the authors through third-party license from Optum and Truven (2 commercial data providers in the United States), and Socialstyrelsen in Sweden. As such, the authors cannot make these data publicly available due to data use agreement. Other researchers can access these data by purchasing a license through Optum and Truven, and placing a data order through the Swedish National Patient Register. Inclusion criteria specified in the 'Materials and methods' section (specifically, the 'Study Definition' subsection) would allow other researchers to identify the same cohort of patients we used for these analyses. Interested individuals may see https://www.optum.com/solutions/prod-nav/product-data.html for more information on accessing Optum data, https://marketscan.truvenhealth.com/marketscanportal/ for more information on accessing Truven (MarketScan) data, and https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/patientregistret/ for more information on accessing the Swedish National Patient Register.

References

Athey S, Tibshirani J, Wager S. Generalized random forests. Annals of Statistics. 2019;47:1148–1178. doi: 10.1214/18-AOS1709. [DOI] [Google Scholar]
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plastic and Reconstructive Surgery. 2011;128:305–310. doi: 10.1097/PRS.0b013e318219c171. [DOI] [PMC free article] [PubMed] [Google Scholar]
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation. 2020;130:2620–2629. doi: 10.1172/JCI137244. [DOI] [PMC free article] [PubMed] [Google Scholar]
Condition Categories Chronic conditions data warehouse. 2020. [May 1, 2021]. https://www2.ccwdata.org/web/guest/condition-categories
Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo Al, De Cobelli F, Dagna L, SARI-RAF Study Group. SARI-RAF Study Group members Interleukin-6 blockade with SARILUMAB in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Annals of the Rheumatic Diseases. 2020;79:1277–1285. doi: 10.1136/annrheumdis-2020-218122. [DOI] [PMC free article] [PubMed] [Google Scholar]
Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Avoidable flaws in observational analyses: An application to statins and cancer. Nature Medicine. 2019;25:1601–1606. doi: 10.1038/s41591-019-0597-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 2007;449:721–725. doi: 10.1038/nature06185. [DOI] [PubMed] [Google Scholar]
Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. American Journal of Epidemiology. 2011;173:761–767. doi: 10.1093/aje/kwq439. [DOI] [PMC free article] [PubMed] [Google Scholar]
GBD 2016 Lower Respiratory Infections Collaborators Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Infectious Diseases. 2018;18:1191–1210. doi: 10.1016/S1473-3099(18)30310-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC, COVID-19 Global Rheumatology Alliance Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician-reported Registry. Annals of the Rheumatic Diseases. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871. [DOI] [PMC free article] [PubMed] [Google Scholar]
Grisanti LA, Woster AP, Dahlman J, Sauter ER, Combs CK, Porter JE. α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. The Journal of Pharmacology and Experimental Therapeutics. 2011;338:648–657. doi: 10.1124/jpet.110.178012. [DOI] [PMC free article] [PubMed] [Google Scholar]
Hartung J, Knapp G, Sinha BK. Statistical Meta-Analysis with Applications. John Wiley & Sons; 2011. [Google Scholar]
Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor--modified T-cell therapy. Blood. 2017;130:2295–2306. doi: 10.1182/blood-2017-06-793141. [DOI] [PMC free article] [PubMed] [Google Scholar]
Ho D, Imai K, King G, MatchIt SE. Nonparametric preprocessing for parametric causal inference. Journal of Statistical Software. 2011;42:i08. doi: 10.18637/jss.v042.i08. [DOI] [Google Scholar]
Holdcroft A. Gender bias in research: how does it affect evidence based medicine? Journal of the Royal Society of Medicine. 2007;100:2–3. doi: 10.1177/014107680710000102. [DOI] [PMC free article] [PubMed] [Google Scholar]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache J-M, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad J-J, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: A cohort study. The Lancet. Rheumatology. 2020;2:e393–e400. doi: 10.1016/S2665-9913(20)30164-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Investigators RC, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. The New England Journal of Medicine. 2021;384:1491–1502. doi: 10.1056/NEJMoa2100433. [DOI] [PMC free article] [PubMed] [Google Scholar]
Konig MF, Powell M, Staedtke V, Bai R-Y, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. The Journal of Clinical Investigation. 2020;130:3345–3347. doi: 10.1172/JCI139642. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P. Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2021;9:99. doi: 10.1016/S2213-2600(21)00099-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959;22:719–748. [PubMed] [Google Scholar]
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews. 2020;19:102537. doi: 10.1016/j.autrev.2020.102537. [DOI] [PMC free article] [PubMed] [Google Scholar]
McMurray RJ. Gender disparities in clinical decision making. JAMA. 1991;266:559–562. doi: 10.1001/jama.1991.03470040123034. [DOI] [PubMed] [Google Scholar]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
Patientregistret Patientregistret. 2021. [May 15, 2020]. https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/patientregistret/
Pedersen SF, Ho YC. SARS-COV-2: A storm is raging. The Journal of Clinical Investigation. 2020;130:2202–2205. doi: 10.1172/JCI137647. [DOI] [PMC free article] [PubMed] [Google Scholar]
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian D-S. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases. 2020;71:762–768. doi: 10.1093/cid/ciaa248. [DOI] [PMC free article] [PubMed] [Google Scholar]
RECOVERY Collaborative Group Dexamethasone in hospitalized patients with covid-19. The New England Journal of Medicine. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. The New England Journal of Medicine. 2021;384:1503–1516. doi: 10.1056/NEJMoa2028700. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika. 1983;70:41–55. doi: 10.1093/biomet/70.1.41. [DOI] [Google Scholar]
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in patients hospitalized with covid-19 pneumonia. The New England Journal of Medicine. 2021;384:20–30. doi: 10.1056/NEJMoa2030340. [DOI] [PMC free article] [PubMed] [Google Scholar]
Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G. Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nature Immunology. 2015;16:1228–1234. doi: 10.1038/ni.3321. [DOI] [PMC free article] [PubMed] [Google Scholar]
Staedtke V, Bai R-Y, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564:273–277. doi: 10.1038/s41586-018-0774-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
Steegen S, Tuerlinckx F, Gelman A, Vanpaemel W. Increasing Transparency Through a Multiverse Analysis. Perspectives on Psychological Science. 2016;11:702–712. doi: 10.1177/1745691616658637. [DOI] [PubMed] [Google Scholar]
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen Y-D, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D’Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK, BACC Bay Tocilizumab Trial Investigators Efficacy of tocilizumab in patients hospitalized with covid-19. The New England Journal of Medicine. 2020;383:2333–2344. doi: 10.1056/NEJMoa2028836. [DOI] [PMC free article] [PubMed] [Google Scholar]
Stuart EA. Matching methods for causal inference: A review and a look forward. Statistical Science. 2010;25:1–21. doi: 10.1214/09-STS313. [DOI] [PMC free article] [PubMed] [Google Scholar]
Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution—A Simulation Study. American Journal of Epidemiology. 2010;172:843–854. doi: 10.1093/aje/kwq198. [DOI] [PMC free article] [PubMed] [Google Scholar]
The top 10 causes of death The top 10 causes of death. 2021. [December 9, 2020]. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Annals of Internal Medicine. 2017;167:268–274. doi: 10.7326/M16-2607. [DOI] [PubMed] [Google Scholar]
Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. Journal of the American Statistical Association. 2018;113:1228–1242. doi: 10.1080/01621459.2017.1319839. [DOI] [Google Scholar]
Whittle J, Fine MJ, Joyce DZ, Lave JR, Young WW, Hough LJ, Kapoor WN. Community-acquired pneumonia: can it be defined with claims data? American Journal of Medical Quality. 1997;12:187–193. doi: 10.1177/0885713X9701200404. [DOI] [PubMed] [Google Scholar]
Yasukawa K, Swarz H, Ito Y. Review of Orthostatic Tests on the Safety of Tamsulosin, a Selective α1A-Adrenergic Receptor Antagonist, Shows Lack of Orthostatic Hypotensive Effects. The Journal of International Medical Research. 2001;29:236–251. doi: 10.1177/147323000102900312. [DOI] [PubMed] [Google Scholar]
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

eLife. doi: 10.7554/eLife.61700.sa1

Decision letter

Editor: Evangelos J Giamarellos-Bourboulis¹

Reviewed by: Jesus Bermejo-Martin, Evdoxia Kyriazopoulou², Evangelos J Giamarellos-Bourboulis³

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

The manuscript deals with the role of previous treatment with α₁ adrenergic receptor antagonists in the prevention of mechanical ventilation and death from pneumonia. The provide important results supporting a protective effect of ⍺1-AR antagonists in ARDS and pneumonia.

Decision letter after peer review:

Thank you for submitting your article "Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, including Evangelos J Giamarellos-Bourboulis as the Reviewing Editor and Reviewer #3, and the evaluation has been overseen by Jos van der Meer as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Jesus Bermejo-Martin (Reviewer #1); Evdoxia Kyriazopoulou (Reviewer #2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

The manuscript outscores the role of previous treatment with α₁ adrenergic receptor antagonists in the prevention of mechanical ventilation and death from pneumonia. The manuscript provides interesting results suggesting a protective effect of ⍺₁-AR antagonists in ARDS and pneumonia I. However, major issues need to be addressed:

1. The type of lower respiratory infection the authors refer to is far too vague; the authors need to focus separately on community-acquired and hospital-acquired infections.

2. We do not agree with matching criteria: there is no doubt that matching is important. However, to be certain of the protective effect of the impact of chronic medication on the outcome of pneumonia, matching should take into consideration comorbidities and severity scores. Although supplementary figures analyse for comorbidities, nothing is done for severity indexes. This is a major limitation.

3. Is HIV infection one of the studied comorbidities?

4. How the authors treat patients who are receiving α₁ adrenergic receptor antagonists for less than 6 months per year?

5. Figure 1 is very difficult to understand. Not even the abbreviations e.g. PNA are provided.

6. The authors state that "our primary research question is whether ⍺₁-AR antagonists can mitigate or prevent cytokine-storm syndrome"…Where are the results demonstrating the impact of ⍺₁-AR antagonists on cytokine levels? The authors demonstrate a statistical protective association between the use of these drugs and the risk of death or mechanical ventilation in patients with ARD or pneumonia. The role of cytokine storm in these syndromes is yet to be elucidated. In example, the authors directly accept the cytokine storm theory in COVID-19. We strongly recommend to revise the title and modulate the work`s objective, since no cytokine data are offered here.

7. How the authors control the potential influence of other treatments? Patients needing of ⍺1-AR antagonists use to be elderly men, and in consequence they often receive multiple chronic treatments.

8. The authors have chosen as outcomes the incidence of mechanical ventilation and the incidence of mechanical ventilation and subsequent death. There is a huge overlap between these two outcomes and moreover, death due to other causes is overseen. We would suggest changing the second outcome with all-cause mortality or adding it as third.

9. The authors describe that they have used five different cohorts of patients. These cohorts are not obviously presented in Figure 2. Moreover, the baseline demographics of patients are nowhere given. Did they differ perhaps in the rate of other comorbidities or severity indexes and these differences confound results? What did they match in their matched analysis?

eLife. 2021 Jun 11;10:e61700. doi: 10.7554/eLife.61700.sa2

Author response

The manuscript outscores the role of previous treatment with α₁ adrenergic receptor antagonists in the prevention of mechanical ventilation and death from pneumonia. The manuscript provides interesting results suggesting a protective effect of α₁-AR antagonists in ARDS and pneumonia I. However, major issues need to be addressed:

1. The type of lower respiratory infection the authors refer to is far too vague; the authors need to focus separately on community-acquired and hospital-acquired infections.

Thank you for raising this important point; we agree that the CAP/HAP separation could be useful if there are differences in outcomes among populations. Unfortunately, making a precise CAP/HAP determination for each patient is not possible in our study using our available claims data; it is also not clear if standard criteria to make this distinction from claims data alone have been defined in the relevant literature. In fact, the literature on identifying pneumonia cases from medical claims data focuses somewhat exclusively on identifying community-acquired or all-cause pneumonia rather than distinguishing CAP/HAP cases [1, 2, 3, 4]. Upon reviewing the relevant CAP-identifying literature, we found that identifying pneumonia cases on a large scale requires automated case identification using administrative data, which – when compared to manual chart review in small studies [3, 5] – exhibits modest sensitivity and specificity. The best distinction we can find for approximating if a case is CAP or HAP using claims data requires knowledge of both the timing of imaging and radiological findings related to time of hospitalization; we have visibility of neither the timing nor the findings of imaging studies as neither exists in our available medical claims data (which only contain overall ICD codes useful for identifying all-cause pneumonia). For example, CAP is defined with pneumonia listed only as the first diagnosis code in Whittle 1997, but Guevara 1999 claims pneumonia in the first five diagnosis code positions greatly increases sensitivity without sacrificing specificity (both heuristics specifically aim to identify CAP cases) [3, 5]. An additional layer of complexity relates to the frequently changing clinical definitions of CAP, HAP, and health care-associated pneumonia (HCAP), a construct abandoned in 2016 [6, 7, 8], over the duration of our retrospective study (2004-2019). In summary, our data limitations, the lack of an accepted process for CAP/HAP determination in medical claims data, and significantly changing clinical definitions over the study period prevent breaking up our all-cause pneumonia analysis.

We have included a note on this topic in the Discussion of our manuscript (Section 3):

“Additionally, future work should consider whether the patients’ respiratory illness is community- or hospital-acquired [5] (a distinction we could not make with our data), since the ensuing severity of ARDS or PNA may differ accordingly.”

2. We do not agree with matching criteria: there is no doubt that matching is important. However, to be certain of the protective effect of the impact of chronic medication on the outcome of pneumonia, matching should take into consideration comorbidities and severity scores. Although supplementary figures analyse for comorbidities, nothing is done for severity indexes. This is a major limitation.

We are uncertain whether the concern over missing severity indices is referring to individual comorbidity severity indices or the more common comorbidity summary indices (e.g., Charlson Comorbidity Index or Elixhauser Comorbidity Index), so we will address both in this response.

We performed several robustness checks that did include the calculated Elixhauser index (using the `comorbidityscores` R package) with available data; these model variants did not meaningfully change our results. We chose to not include summary indices (e.g., the Elixhauser or Charlson) in our main results because we only observe health data in the one year prior, and it may not be reasonable to classify individuals with no inpatient or outpatient visits in the prior year as individuals with perfect health per these indices (a frequent occurrence in our data).

We invested significant time considering the different measures of severity indices found in the prior literature, and chose to use a method aligned with OHDSI [9] as described in this paragraph. It is true that we do not address severity at the level of each comorbidity; this is primarily due to lack of visibility on required data used to compute certain comorbidity severity scores (e.g., laboratory results, questionnaires / physician’s examinations, and certain sociodemographic data). Additionally, adding a severity index as an additional variable for each comorbidity could lead to more instability in our models by dramatically increasing the number of covariates (with severity indices either as additional covariates or as additional levels beyond our current binary representation for each comorbidity). The matching and regression methods used for all analyses do, however, involve nonspecific comorbidity severity measures as is standard per OHDSI. As indicated in the Supplementary Figures, we use covariates including: total weeks with inpatient admissions in the prior year, total outpatient visits in the prior year, total prior days as an inpatient in the prior year, and total weeks with prior inpatient stays in the previous two months (corresponding to STAYS12, VISIT12, DAYS12, and STAYS2, respectively). In addition, our matching criteria require an exact match on patient age and a nearest-neighbor match on all remaining covariates, which include comorbidities and the log-transformed values of the severity measures listed above.

We include the following addendum to our manuscript in Section 4.6:

“To assess invariance of our results to definitional choices, we adjusted the definition of exposure to α₁-AR antagonists (e.g., requiring regular use of α₁-AR antagonists within the prior 3 months rather than 12 months, or excluding α₁-AR antagonist users who simultaneously take one of the 12 most common drugs appearing in the cohorts studied) as well as the definitions of certain confounders (e.g., combining three cardiovascular confounders into one indicator, including different metrics of prior inpatient or outpatient stays, including comorbidity severity indices, or including additional comorbidities such as human immunodeficiency virus [HIV] infection).”

3. Is HIV infection one of the studied comorbidities?

We have confirmed our results do not meaningfully change when including HIV (ICD codes 042 and B20) as a covariate; see Author response image 1. We did not include HIV infection as a comorbidity in our main analysis since there is extremely rare (<1%) incidence of HIV in our cohorts potentially leading to instability in matching; but, our work is broadly robust to different sets of relevant comorbidities (e.g., using a broader category of cardiovascular comorbidities rather than our chosen selection).

As noted in our response to the second point above, we include the following addendum to our manuscript in Section 4.6:

“To assess invariance of our results to definitional choices, we adjusted the definition of exposure to α₁-AR antagonists (e.g., requiring regular use of α₁-AR antagonists within the prior 3 months rather than 12 months, or excluding ⍺₁-AR antagonist users who simultaneously take one of the 12 most common drugs appearing in the cohorts studied) as well as the definitions of certain confounders (e.g., combining three cardiovascular confounders into one indicator, including different metrics of prior inpatient or outpatient stays, including comorbidity severity indices, or including additional comorbidities such as human immunodeficiency virus [HIV] infection).”

4. How the authors treat patients who are receiving α₁ adrenergic receptor antagonists for less than 6 months per year?

These few patients are removed from the retrospective analysis entirely, so our treatment effect is based on directly comparing patients known to be long-term users of alpha blockers (i.e., using for more than 6 months of the year) to patients known to have never in the prior year used alpha blockers.

This is clarified in Section 4.1 of the manuscript:

“We exclude patients having a medical possession ratio greater than 0% and less than 50% of the relevant drug class or drug (equivalently, we exclude patients who do use ⍺1-AR antagonists, but for less than six months of the prior year).”

5. Figure 1 is very difficult to understand. Not even the abbreviations e.g. PNA are provided.

Thank you for noting this; we have revised the Figure 1 caption accordingly to define ARDS, and we updated Figure 2 to eliminate the PNA abbreviation and include more explanation in the caption.

We additionally remove the PNA abbreviation from the paper writ large, and use the term ‘pneumonia’ instead.

6. The authors state that "our primary research question is whether α₁-AR antagonists can mitigate or prevent cytokine-storm syndrome"…Where are the results demonstrating the impact of α₁-AR antagonists on cytokine levels? The authors demonstrate a statistical protective association between the use of these drugs and the risk of death or mechanical ventilation in patients with ARD or pneumonia. The role of cytokine storm in these syndromes is yet to be elucidated. In example, the authors directly accept the cytokine storm theory in COVID-19. We strongly recommend to revise the title and modulate the work`s objective, since no cytokine data are offered here.

Thank you for this helpful contextualization; we believe that, unfortunately, the reviewers were sent our initial submission rather than our final submission to review. Your comments were resolved in our previous (i.e., ‘final’ submission) to eLife. While tracked changes in the manuscript will not reflect these changes, we left comments on the document where the relevant language exists in the Introduction and Discussion.

To clarify, we received similar feedback upon first submitting the article suggesting we reduce references to cytokine storms as we do not directly study cytokine levels nor have the ability to measure them in claims data. Before submitting our final manuscript, we incorporated this feedback by changing the title and introductory and discussion paragraphs to reflect that our hypothesis addresses the role of alpha blockers in lower respiratory tract infections, a hypothesis we connect to our prior cytokine storm study in mice. It appears that the version of our paper that went to reviewers did not reflect these changes (the quoted sentence identified by the reviewer does not exist verbatim in our most recently submitted manuscript).

We also agree with the reviewer that our understanding of immunopathogenesis and the nomenclature of cytokine dysregulation in patients with severe COVID-19 and other respiratory tract infections is evolving. We have used cytokine storm syndrome as an umbrella term to designate hyperinflammation rather than more narrowly used terms such as cytokine release syndrome (CRS) as seen in CAR-T cell therapy, hemophagocytic lymphohistiocytosis (HLH) with perforin pathway loss of function mutations, or macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis, which have phenotypic similarities and overlapping but likely not identical immunopathogeneses [10]. To address the reviewer’s concerns, we have changed the nomenclature in the manuscript to hyperinflammation when extrapolating to mechanism.

7. How the authors control the potential influence of other treatments? Patients needing of α₁-AR antagonists use to be elderly men, and in consequence they often receive multiple chronic treatments.

We control for confounders in our study (i.e., the comorbidities that would necessitate other treatments). We do not control for treatments themselves given the high dimensionality of potential treatments, the relatively small number of non-alpha-blocker treatments being taken consistently and in tandem with alpha-blockers, and the lack of evidence that other treatments would impact respiratory outcomes in a way that would not be accounted for by the relevant comorbidity.

Because, as you mention, the patients needing ⍺₁-AR antagonists are often elderly men, we do in particular restrict our analyses to men over the age of 45, and adjust for age, age squared, and age cubed in the adjusted analyses (Section 4.3); we require an exact match on age in the matching analyses (Section 4.4).

Additionally, we have run robustness checks where our analyses are conducted for a treatment defined as taking ⍺₁-AR antagonists and individually excluding each of the most commonly taken drugs among the relevant patients (furosemide, simvastatin, amlodipine, atorvastatin, lisinopril, potassium chloride, carvedilol, omeprazole, allopurinol, gabapentin, levothyroxine sodium, and metoprolol); roughly 70-80% of ⍺₁-AR antagonist takers are also taking one of these additional drugs, so we exclude users of these drugs one drug at a time in separate analyses. The results for each drug exclusion are consistent with the main findings presented in our paper, wherein treatment involving ⍺₁-AR antagonists yields odds ratios < 1 for both relevant outcomes (mechanical ventilation and subsequent death).

As noted in our response to the second point above, we include a comment on this in Section 4.6:

“To assess invariance of our results to definitional choices, we adjusted the definition of exposure to α₁-AR antagonists (e.g., requiring regular use of α₁-AR antagonists within the prior 3 months rather than 12 months, or excluding α₁-AR antagonist users who simultaneously take one of the 12 most common drugs appearing in the cohorts studied) as well as the definitions of certain confounders (e.g., combining three cardiovascular confounders into one indicator, including different metrics of prior inpatient or outpatient stays, including comorbidity severity indices, or including additional comorbidities such as human immunodeficiency virus [HIV] infection).”

8. The authors have chosen as outcomes the incidence of mechanical ventilation and the incidence of mechanical ventilation and subsequent death. There is a huge overlap between these two outcomes and moreover, death due to other causes is overseen. We would suggest changing the second outcome with all-cause mortality or adding it as third.

The goal of our analysis is to study outcomes related to respiratory illness; the most direct way to study mortality outcomes in this context is to count deaths that coincide with mechanical ventilation. As such, we do not believe all-cause mortality is as relevant a metric to study our particular research question.

That said, we have found that our results are robust to additional outcomes, such as all-cause mortality and the combined outcome of death or ventilation (see Author response image 2); the resulting odds ratios are in line with our findings based on the metrics of ventilation, and death and ventilation.

We have amended our manuscript in Section 4.1 to include:

“We focused on death associated with respiratory failure to avoid counting deaths due to other diseases (many of the patients were hospitalized for other reasons), but note that our findings are robust to outcomes defined instead by all-cause mortality, with OR < 1.”

9. The authors describe that they have used five different cohorts of patients. These cohorts are not obviously presented in Figure 2. Moreover, the baseline demographics of patients are nowhere given. Did they differ perhaps in the rate of other comorbidities or severity indexes and these differences confound results? What did they match in their matched analysis?

Thank you for raising this concern. Figure 2 only contains statistics for four cohorts – pneumonia patients from the Marketscan and Optum databases, and ARD patients from the Marketscan and Optum databases (corresponding to n_M, n_O under the left branch of the CONSORT diagram, and n_M, n_O under the right branch of the CONSORT diagram, respectively); we had excluded counts on the fifth cohort (Swedish National Patient Register) because a different set of inclusion/exclusion criteria were used (see section 4.7).

We augment the Figure 2 caption as follows:

“This diagram only regards four of the five cohorts studied; the fifth cohort (the Swedish National Patient Register) uses a different set of inclusion/exclusion criteria (see Section 4.7 for criteria description, and Supplementary Figure 3—figure supplement 1 for information on dataset characteristics).”

Baseline demographics of the patients for each cohort were shown in panel (i) of Supplementary Figure 3—figure supplements 2-5; we have augmented Supplementary Figure 3—figure supplement 1 to include demographic distributions for the pneumonia cohort from the Swedish National Patient Register database (which includes all males, aged 45-85). The primary driver of demographic differences among cohorts is that the MarketScan database only includes patients up to age 65, whereas the other cohorts include patients up to age 85 (see description in section 4.1); as such, the MarketScan cohorts tend to have generally healthier patients. However, we resolve this concern by adjusting for confounders such as age and comorbidity. For the Mahalanobis matching analysis (described in point #2 of this response), each cohort only matches within itself.

References:

[1] Yu O, Nelson JC, Bounds L, Jackson LA. Classification algorithms to improve the accuracy of identifying patients hospitalized with community-acquired pneumonia using administrative data. Epidemiology and Infection. 2011 Sep;139(9):1296-306.

[2] van de Garde EM, Oosterheert JJ, Bonten M, Kaplan RC, Leufkens HG. International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia. Journal of clinical epidemiology. 2007 Aug 1;60(8):834-8.

[3] Guevara RE, Butler JC, Marston BJ, Plouffe JF, File Jr TM, Breiman RF. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. American journal of epidemiology. 1999 Feb 1;149(3):282-9.

[4] Skull SA, Andrews RM, Byrnes GB, Campbell DA, Nolan TM, Brown GV, Kelly HA. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged⩾ 65 years. Epidemiology and Infection. 2008 Feb;136(2):232-40.

[5] Whittle J, Fine MJ, Joyce DZ, Lave JR, Young WW, Hough LJ, Kapoor WN. Community-acquired pneumonia: can it be defined with claims data?. American Journal of Medical Quality. 1997 Dec;12(4):187-93.

[6] American Thoracic Society. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine. 2004 Oct;171:388-416.

[7] Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L, Napolitano L, O’Grady N, Bartlett J, Carratalà J, El Solh A, Ewig S, Fey P, File T, Restrepo M, Roberts J, Waterer G, Cruse P, Knight S, Brozek J. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016 Jul;63(5):61-111.

[8] Kumar S, Yassin A, Bhowmick T, Dixit D. Recommendations From the 2016 Guidelines for the Management of Adults with Hospital-Acquired or Ventilator-Associated Pneumonia. Pharmacy and Therapeutics. 2017 Dec;42(12):767-772.

[9] Reps J and Chen Y. Applying the Lossless Distributed Linear Mixed Model to integrate heterogeneous COVID-19 hospitalization data across the OHDSI Network. OHDSI Studies. 2020 Aug.

[10] Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis and Rheumatology. 2020 Jul;72(7):1059-63.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Source code 1. R Markdown code to run retrospective analysis and generate figures.

elife-61700-supp1.zip^{(28.5KB, zip)}

Source code 2. R script to generate cohorts and perform propensity matching.

elife-61700-supp2.zip^{(5.7KB, zip)}

Transparent reporting form

elife-61700-transrepform1.docx^{(246KB, docx)}

Data Availability Statement

[bib1] Athey S, Tibshirani J, Wager S. Generalized random forests. Annals of Statistics. 2019;47:1148–1178. doi: 10.1214/18-AOS1709. [DOI] [Google Scholar]

[bib2] Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plastic and Reconstructive Surgery. 2011;128:305–310. doi: 10.1097/PRS.0b013e318219c171. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib3] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation. 2020;130:2620–2629. doi: 10.1172/JCI137244. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib4] Condition Categories Chronic conditions data warehouse. 2020. [May 1, 2021]. https://www2.ccwdata.org/web/guest/condition-categories

[bib5] Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo Al, De Cobelli F, Dagna L, SARI-RAF Study Group. SARI-RAF Study Group members Interleukin-6 blockade with SARILUMAB in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study. Annals of the Rheumatic Diseases. 2020;79:1277–1285. doi: 10.1136/annrheumdis-2020-218122. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib6] Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Avoidable flaws in observational analyses: An application to statins and cancer. Nature Medicine. 2019;25:1601–1606. doi: 10.1038/s41591-019-0597-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib7] Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, Van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 2007;449:721–725. doi: 10.1038/nature06185. [DOI] [PubMed] [Google Scholar]

[bib8] Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. American Journal of Epidemiology. 2011;173:761–767. doi: 10.1093/aje/kwq439. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib9] GBD 2016 Lower Respiratory Infections Collaborators Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Infectious Diseases. 2018;18:1191–1210. doi: 10.1016/S1473-3099(18)30310-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib10] Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham KD, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Yazdany J, Machado PM, Robinson PC, COVID-19 Global Rheumatology Alliance Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician-reported Registry. Annals of the Rheumatic Diseases. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib11] Grisanti LA, Woster AP, Dahlman J, Sauter ER, Combs CK, Porter JE. α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages. The Journal of Pharmacology and Experimental Therapeutics. 2011;338:648–657. doi: 10.1124/jpet.110.178012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib12] Hartung J, Knapp G, Sinha BK. Statistical Meta-Analysis with Applications. John Wiley & Sons; 2011. [Google Scholar]

[bib13] Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor--modified T-cell therapy. Blood. 2017;130:2295–2306. doi: 10.1182/blood-2017-06-793141. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib14] Ho D, Imai K, King G, MatchIt SE. Nonparametric preprocessing for parametric causal inference. Journal of Statistical Software. 2011;42:i08. doi: 10.18637/jss.v042.i08. [DOI] [Google Scholar]

[bib15] Holdcroft A. Gender bias in research: how does it affect evidence based medicine? Journal of the Royal Society of Medicine. 2007;100:2–3. doi: 10.1177/014107680710000102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib16] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib17] Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache J-M, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad J-J, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: A cohort study. The Lancet. Rheumatology. 2020;2:e393–e400. doi: 10.1016/S2665-9913(20)30164-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib18] Investigators RC, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. The New England Journal of Medicine. 2021;384:1491–1502. doi: 10.1056/NEJMoa2100433. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib19] Konig MF, Powell M, Staedtke V, Bai R-Y, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. The Journal of Clinical Investigation. 2020;130:3345–3347. doi: 10.1172/JCI139642. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib20] Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P. Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2021;9:99. doi: 10.1016/S2213-2600(21)00099-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib21] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959;22:719–748. [PubMed] [Google Scholar]

[bib22] McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews. 2020;19:102537. doi: 10.1016/j.autrev.2020.102537. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib23] McMurray RJ. Gender disparities in clinical decision making. JAMA. 1991;266:559–562. doi: 10.1001/jama.1991.03470040123034. [DOI] [PubMed] [Google Scholar]

[bib24] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib25] Patientregistret Patientregistret. 2021. [May 15, 2020]. https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/patientregistret/

[bib26] Pedersen SF, Ho YC. SARS-COV-2: A storm is raging. The Journal of Clinical Investigation. 2020;130:2202–2205. doi: 10.1172/JCI137647. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib27] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian D-S. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases. 2020;71:762–768. doi: 10.1093/cid/ciaa248. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib28] RECOVERY Collaborative Group Dexamethasone in hospitalized patients with covid-19. The New England Journal of Medicine. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib29] Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. The New England Journal of Medicine. 2021;384:1503–1516. doi: 10.1056/NEJMoa2028700. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib30] Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika. 1983;70:41–55. doi: 10.1093/biomet/70.1.41. [DOI] [Google Scholar]

[bib31] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib32] Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in patients hospitalized with covid-19 pneumonia. The New England Journal of Medicine. 2021;384:20–30. doi: 10.1056/NEJMoa2030340. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib33] Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G. Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nature Immunology. 2015;16:1228–1234. doi: 10.1038/ni.3321. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib34] Staedtke V, Bai R-Y, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564:273–277. doi: 10.1038/s41586-018-0774-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib35] Steegen S, Tuerlinckx F, Gelman A, Vanpaemel W. Increasing Transparency Through a Multiverse Analysis. Perspectives on Psychological Science. 2016;11:702–712. doi: 10.1177/1745691616658637. [DOI] [PubMed] [Google Scholar]

[bib36] Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen Y-D, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D’Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK, BACC Bay Tocilizumab Trial Investigators Efficacy of tocilizumab in patients hospitalized with covid-19. The New England Journal of Medicine. 2020;383:2333–2344. doi: 10.1056/NEJMoa2028836. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib37] Stuart EA. Matching methods for causal inference: A review and a look forward. Statistical Science. 2010;25:1–21. doi: 10.1214/09-STS313. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib38] Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution—A Simulation Study. American Journal of Epidemiology. 2010;172:843–854. doi: 10.1093/aje/kwq198. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib39] The top 10 causes of death The top 10 causes of death. 2021. [December 9, 2020]. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

[bib40] VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Annals of Internal Medicine. 2017;167:268–274. doi: 10.7326/M16-2607. [DOI] [PubMed] [Google Scholar]

[bib41] Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. Journal of the American Statistical Association. 2018;113:1228–1242. doi: 10.1080/01621459.2017.1319839. [DOI] [Google Scholar]

[bib42] Whittle J, Fine MJ, Joyce DZ, Lave JR, Young WW, Hough LJ, Kapoor WN. Community-acquired pneumonia: can it be defined with claims data? American Journal of Medical Quality. 1997;12:187–193. doi: 10.1177/0885713X9701200404. [DOI] [PubMed] [Google Scholar]

[bib43] Yasukawa K, Swarz H, Ito Y. Review of Orthostatic Tests on the Safety of Tamsulosin, a Selective α1A-Adrenergic Receptor Antagonist, Shows Lack of Orthostatic Hypotensive Effects. The Journal of International Medical Research. 2001;29:236–251. doi: 10.1177/147323000102900312. [DOI] [PubMed] [Google Scholar]

[bib44] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection

Allison Koenecke

Michael Powell

Ruoxuan Xiong

Zhu Shen

Nicole Fischer

Sakibul Huq

Adham M Khalafallah

Marco Trevisan

Pär Sparen

Juan J Carrero

Akihiko Nishimura

Brian Caffo

Elizabeth A Stuart

Renyuan Bai

Verena Staedtke

David L Thomas

Nickolas Papadopoulos

Ken W Kinzler

Bert Vogelstein

Shibin Zhou

Chetan Bettegowda

Maximilian F Konig

Brett D Mensh

Joshua T Vogelstein

Susan Athey

Roles

Abstract

Introduction

Figure 1. Model of clinical progression of respiratory dysfunction from local infection to hyperinflammation.

Results

Participants

Figure 2. CONSORT flow diagram for four claims datasets where M represents MarketScan and O represents Optum; ARD represents acute respiratory distress.

Cohort-specific results

Federated results

Figure 3. Cohorts across datasets (MarketScan and Optum) associated with the same disease (ARD in top row, pneumonia in bottom row) were pooled using federated causal learning techniques described in Materials and methods.

Figure 3—figure supplement 1. Patients from the Swedish National Patient Register with pneumonia.

Figure 3—figure supplement 2. Patients from MarketScan Research Database with acute respiratory distress.

Figure 3—figure supplement 3. Patients from Optum with acute respiratory distress.

Figure 3—figure supplement 4. Patients from MarketScan Research Database with pneumonia.

Figure 3—figure supplement 5. Patients from Optum with pneumonia.

Discussion

Materials and methods

Study definitions

Unadjusted analysis

Adjusted analysis

Matched analysis

Federated analysis

Sensitivity analysis

Figure 4. We plot the proportion of exposed and unexposed patients having any inpatient admissions a certain number of months prior to the first ARD or pneumonia admission date, and present corresponding confidence intervals.

Sweden National Patient Register

Acknowledgements

Funding Statement

Contributor Information

Funding Information

Additional information

Competing interests

Author contributions

Ethics

Additional files

Data availability

References

Decision letter

Roles

Author response

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases